Doximity Slashes FY23 Outlook After Q1 Beat, Shares Plunge

Doximity Inc DOCS reported first-quarter FY23 sales of $90.6million, an increase of 24.7% year-over-year, beating the consensus of $89.3 million. The adjusted EPS of $0.14 beat the consensus of $0.10.

The gross margin contracted by 344 bps to 85.6%. The operating income declined by 12.8% Y/Y to $21.68 million, and the margin fell to 23.9% from 34.2% in 1Q22.

Adjusted EBITDA of $33.5 million grew 8% Y/Y, representing adjusted EBITDA margins of 37% versus 43% a year ago.

Doximity generated an operating cash flow of $44.8 million versus $33.2 million, and a free cash flow of $42.6 million, versus $32.4 million.

"We had a strong Q3 led by our existing clients as our net revenue retention rate hit 171%," said Jeff Tangney, co-founder & CEO. "Our telehealth platform grew to 350,000 active providers."

2Q23 Outlook: Doximity expects revenue of $99.5 million - $100.5 million vs. a consensus of $105.26 million, compared to the consensus of $89.26 million. It expects an adjusted EBITDA of $40 million - $41 million.

FY23 Outlook: The Company forecasts revenue of $424 million- $432 million (prior expectations of $454 million - $458 million), versus the consensus of $455.23 million, with adjusted EBITDA of $178 million and $186 million (prior $192 million and $196 million).

Price Action: DOCS shares are trading lower by 16.27% at $33.75 during the post-market session on Thursday.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceAfter-Hours CenterMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!